News Archive
Here you will find archived C-Path news events. Please feel free to browse the documents and news releases below to learn more about what have been doing here at the Critical Path Institute.
2008 News...
November 2008 - Amgen Biomarker Toolkit - Biomarker Backgrounder...
Personalized Medicine:
In clinical practice, personalized medicine refers to the use of new methods of molecular analysis to better manage a patient's disease...
November 2008 - C-Path is No. 7 in Reader's Digest list of 18 big ideas to fix healthcare now...
The November 2008 issue of Reader's Digest lists 18 big ideas to fix healthcare now and the Critical Path Insitute is listed as number 7.
November 2008 - Science Foundation Arizona Invests to Increase Arizona's Biomedical Capacity...
The Critical Path Institute (C-Path), has been awarded a $9 million investment grant from Science Foundation Arizona (SFAz).
June 2008 - C-Path leads novel transatlantic drug safety effort...
Companies receive go ahead from FDA and EMEA to use new improved tests when assessing safety of new drugs.
June 2008 - FDA & EMEA to consider additional test results when assessing new drug safety...
In the first use of a framework allowing submission of a single application to the two agencies, the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) worked together to allow drug companies to submit the results of seven new tests that evaluate kidney damage during animal studies of new drugs.
April 2008 - FDA soon may support biomarker tests...
The Food and Drug Administration is poised to throw its support behind a powerful new method of predicting the safety of experimental drugs, a step that could help pharmaceutical companies bring treatments to market more quickly - and reduce patients' risk.
March 2008 - Tucson Citizen - Blood thinner safety effort touted...
A Tucson-based research institute says it is improving the safety of a widely used blood thinning drug.
March 2008 - US News & World Report - Genetic tests predict response to Warfarin...
Variations of a gene that determines a person's sensitivity to warfarin are important in determining the initial doses of the anti-clotting drug, researchers report.
February 2008 - Alastair J.J. Wood joins the Critical Path Institute Board of Directors...
Dr. Alastair J.J. Wood, drug development authority, frequent advisor to the Food and Drug Administration (FDA) and former Assistant Vice Chancellor for Research at Vanderbilt University was recently named to the Board of Directors of the Critical Path Institute.
January 2008 - Peter Corr joins the Critical Path Institute Board of Directors...
The Critical Path Institute today announced that Peter B. Corr, Ph.D., has joined its Board of Directors. Dr. Corr has more than 30 years of pharmacology and pharmaceutical development experience as both an academician and a senior executive in the pharmaceutical industry.
2007 News...
Thanks to C-Path's role as an independent, neutral third party, it has been successful in bringing together scientists from the FDA, the industry it regulates and academia.
October 2007 - C-Path Awarded Grant to Continue Drug Safety Work...
The Critical Path Institute (C-Path) announced the receipt of a $4 million grant from the Agency for Healthcare Research and Quality (AHRQ) to continue support for its Arizona Center for Education and Research on Therapeutics (AzCERT).
October 2007 - C-Path and Ventana Medical Systems to collaborate...
The Critical Path Institute (C-Path) and Ventana Medical Systems, Inc. (Ventana) (NASDAQ: VMSI) today released additional information about C-Path's $2.1 million grant from Science Foundation Arizona (SFAz) to fund a collaboration project with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to develop a standard testing and evaluation process for companion diagnostics and their associated targeted cancer therapies.
Science Foundation Arizona (SFAz), through its Strategic Research Group (SRG) program, today announced that it is granting nearly $10 million to eight outstanding research collaborations throughout the state.
To address the issues surrounding a decade-long decrease in the number of new drug approvals, the U.S. Food and Drug Administration (FDA) in 2004 published a report titled Challenge and Opportunity on the Critical Path to New Medical Products.
May 2007 - C-Path makes progress to safely speed medical discoveries to market...
William Mattes of C-Path spoke at the Arizona Pavillion May 8th 2007 about the Predictive Safety Testing Consortium.
April 2007 - Pharmaceutical companies and FDA making strides...
Developing a new drug is a costly and time-intensive venture. It often takes years to safely develop, test, and ultimately gain Food and Drug Administration approval to bring the drugs to market.
March 2007 - Raymond Woosley, M.D., Ph.D., provides expert testimony in congressional hearings...
President and CEO of The Critical Path Institute (C-Path) provided testimony and answered questions about drug development yesterday at the Committee on Energy and Commerce's Subcommittee Hearing on Oversight and Investigations entitled "The Adequacy of FDA Efforts to Assure the Safety of the Drug Supply."
March 2007 - C-Path adopts Rosetta Resolver® System for the PSTC...
Rosetta Biosoftware announced today that The Critical Path Institute (C-Path) adopted the Rosetta Resolver® system for C-Path's Predictive Safety Testing Consortium.
2006 News...
The Critical Path Institute (C-Path) today announced seven new members that have recently joined the Predictive Safety Testing Consortium (PSTC)...
November 2006 - Tucson nonprofit seeks to get cures to patients faster...
A little-noticed 2004 report from the Food and Drug Administration contained a bombshell. Although spending on research and development had been rising for the previous decade, applications for new drugs and medical products had been falling.
September 2006 - C-Path receives $675,000.00 award for FDA collaboration...
The Critical Path Institute (C-Path) has received $675,000 from the US Food and Drug Administration (FDA) for the first year of what is anticipated to be a multi-year, multi phased research program in cardiovascular disease.
April 2006 - C-Path announces the appointment of Jeffery Cossman, M.D., as Chief Scientific Officer...The Critical Path Institute (C-Path), today announced the appointment of Jeffrey Cossman, M.D., an internationally recognized expert in molecular pathology, to the position of Chief Scientific Officer.
April 2006 - Valley Fever cure a step closer...
The federal government is backing the first potential cure for valley fever, a serious lung disease that has spiked in recent years and afflicted thousands of Arizonans.
March 2006 - C-Path forms drug testing pact...
The Tucson-based Critical Path Institute on Thursday announced an unprecedented agreement with eight major pharmaceutical companies to share drug-testing methods in an effort to improve drug safety.
March 2006 - FDA release: The Predictive Safety Testing Consortium...
The Food and Drug Administration (FDA) and The Critical Path Institute (C-Path) today announced the formation of the Predictive Safety Testing Consortium between C-Path and five of America’s largest pharmaceutical companies to share internally developed laboratory methods to predict the safety of new treatments before they are tested in humans.
February 2006 - Drug research institute adds liason from UA...
The retired head of research at the University of Arizona has joined the Tucson-based Critical Path Institute, a UA- and FDA-affiliated drug research institute, as head of its affiliations with research universities.
January 2006 - C-Path to spur medical innovation...
We all remember the Vioxx scare and authorities say it could happen again. However, the FDA is stepping up its efforts to improve the safety of prescription drugs and here in Tucson a research group is piloting a program to examine and detect them carefully.